Latest Financial Results
Q3 2024
Latest Annual Filing
For Fiscal Year Ending Dec 31, 2023
Report Links
Email Alerts
Sign up today and receive company updates straight to your inbox.
Company Overview
Avenue Therapeutics, Inc. (Nasdaq: ATXI) is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases. The Company is currently developing three assets including AJ201, a first-in-class asset for spinal and bulbar muscular atrophy, BAER-101, an oral small molecule selective GABA-A α2/3 receptor positive allosteric modulator for CNS diseases, and IV Tramadol, which is in Phase 3 clinical development for the management of moderate-to-moderately-severe pain in adults in a medically supervised healthcare setting. Avenue is headquartered in Miami, FL and was founded by Fortress Biotech, Inc. (Nasdaq: FBIO). For more information, visit www.avenuetx.com.
Stock Information
IR Contacts
Headquarters
Avenue Therapeutics, Inc.
1111 Kane Concourse
Suite 301
Bay Harbor Islands, FL 33154
Investor Relations
Jaclyn Jaffe
T: 781-652-4500
ir@avenuetx.com
Transfer Agent
VStock Transfer, LLC
18 Lafayette Place
Woodmere, NY 11598
T: 212-828-8436
info@vstocktransfer.com
https://www.vstocktransfer.com